Chronic HBV treatment with xalnesiran plus immunomodulator confers highest HBsAg loss
Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine. “Functional cure — defined as a sustained loss of HBsAg and undetectable HBV DNA at 24 weeks after finite-duration therapy — is a desired